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Abstract
Background: Basal-like constitutes an important molecular subtype of breast cancer characterised by an aggressive
behaviour and a limited therapy response. The outcome of patients within this subtype is, however, divergent. Some
individuals show an increased risk of dying in the first five years, and others a long-term survival of over ten years after
the diagnosis. In this study, we aim at identifying markers associated with basal-like patients’ survival and
characterising subgroups with distinct disease outcome.
Methods: We explored the genomic and transcriptomic profiles of 351 basal-like samples from the METABRIC and
ROCK data sets. Two selection methods, labelled Differential and Survival filters, were employed to determine
genes/probes that are differentially expressed in tumour and control samples, and are associated with overall survival.
These probes were further used to define molecular subgroups, which vary at the microRNA level and in DNA copy
number.
Results: We identified the expression signature of 80 probes that distinguishes between two basal-like subgroups
with distinct clinical features and survival outcomes. Genes included in this list have been mainly linked to cancer
immune response, epithelial-mesenchymal transition and cell cycle. In particular, high levels of CXCR6, HCST, C3AR1
and FPR3 were found in Basal I; whereas HJURP, RRP12 and DNMT3B appeared over-expressed in Basal II. These genes
exhibited the highest betweenness centrality and node degree values and play a key role in the basal-like breast
cancer differentiation. Further molecular analysis revealed 17 miRNAs correlated to the subgroups, including
hsa-miR-342-5p, -150, -155, -200c and -17. Additionally, increased percentages of gains/amplifications were detected
on chromosomes 1q, 3q, 8q, 10p and 17q, and losses/deletions on 4q, 5q, 8p and X, associated with reduced survival.
Conclusions: The proposed signature supports the existence of at least two subgroups of basal-like breast cancers
with distinct disease outcome. The identification of patients at a low risk may impact the clinical decisions-making by
reducing the prescription of high-dose chemotherapy and, consequently, avoiding adverse effects. The recognition of
other aggressive features within this subtype may be also critical for improving individual care and for delineating
more effective therapies for patients at high risk.
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Background
Approximately 15% of all breast cancer cases are of basal-
like subtype, often aggressive and highly recurrent lesions
[1–3]. Basal-like breast cancers (BLBCs) are defined by
the lack of expression of the hormone receptors oestro-
gen (ER) and progesterone (PR), and the human epidermal
growth factor receptor-2 (HER2) [4, 5]. Histologically,
these tumours show high grade, high mitotic indices,
presence of central necrotic or fibrotic zones, pushing
borders of invasion, lymphocytic infiltrate and atypical
medullary features [6]. The breast basal cell layer is also
characterised by high expression of cytokeratins (CK5/6,
CK14, and CK17) and epidermal growth factor receptor
(EGFR), amongst other markers [7–11]. All these features
contribute to the limited therapeutic response and there-
fore impact in the refractory nature of these tumours
[12, 13]. Thus, patients diagnosed with BLBC have a poor
prognosis and a short-term disease-free and overall sur-
vival [14]. A better understanding of the pathophysiology
and molecular basis of basal-like tumours is necessary to
delineate patient outcomes.
At the molecular level, basal-like tumours are consid-
ered more homogeneous than the immunohistochem-
ically defined triple-negative breast cancers (TNBCs),
even though the terminologies are used interchangeably
[1, 15]. Despite the relative molecular homogeneity,
patients within this group still show divergent disease out-
comes [12, 14, 16]: some patients show high mortality and
recurrence rates within the first 3-5 years, in contrast to
others who survive over 10 years – with no recurrence –
following the diagnosis [12, 14, 16]. For the latter group,
the prognosis is better than those of luminal breast cancer
subtype [8, 17]. These observations suggest that BLBCs
may be composed of at least two clinically distinct groups,
with poor or excellent survival [10]. The molecular char-
acterisation of these basal-like tumours is of particular
interest in medicine since it may bring new insights to
the disease understanding and management. Identifying
markers andmechanisms involved in the differentiation of
BLBCs is therefore an essential progression towards this
end. Moreover, it would allow the development of tailored
treatments with more effective individual response, lead-
ing to more personalised and conservative interventions
for breast cancers [18].
Recent investigation of TNBCs pointed to the exis-
tence of intrinsic basal-like subtypes, with distinct molec-
ular patterns [19–21]. The stratification performed and
described by Lehmann et al. (2011) [19] revealed the
involvement of enriched cell cycle and cell division com-
ponents in Basal-like 1 (BL1); growth factor signalling,
glycolisis and gluconeogenesis pathways in Basal-like 2
(BL2); and immune cell processes in Immunomodula-
tory (IM). The authors also determined two other groups
partially overlapping the basal-like subtype defined
by the PAM50 classifier [22]: Mesenchymal (M) and
Mesenchymal stem-like (MSL). Alternatively, Burstein
and colleagues [20] defined the Basal-Like Immune-
Suppressed (BLIS) and Basal-Like Immune-Activated
(BLIA) subtypes. The former tumour type is charac-
terised by multiple SOX family transcription factors,
while the latter is described by Stat signal transduc-
tion molecules and cytokines. More recently, Jézéquel
et al. (2015) [21] pointed to two other groups: a
basal-like with low immune response and high M2-like
macrophages, and a basal-enriched with high immune
response and low M2-like macrophages. All studies
above described have focused on investigating the
molecular heterogeneity of TNBCs, partially supporting
each other.
Multi-gene models have also been applied to predict
breast cancer subtype [22, 23], recurrence [24] and sur-
vival [25, 26]. The selection of genes across samples has
generally been associated with hormonal expression levels
and proliferation modules. Since BLBCs and TNBCs are
hormone receptor (ER and PR) negative and highly prolif-
erative, the prediction power of markers to further sepa-
rate patients at risk within these groups is of limited value
in the current models [27]. Clinical assays independently
modelling triple-negative samples have revealed supe-
rior ability in predicting outcomes of early stage tumours
[28, 29]. These assays andmost approaches, however, have
focused on the immunohistochemically defined TNBCs
[10, 30, 31]. A more robust approach for characteris-
ing BLBC outcomes is yet to be developed. Accordingly,
a proper investigation of BLBCs remains mandatory
and determinant for patients diagnosed within this
subtype [9].
As the classification of TNBCs is not an ideal surro-
gate for defining BLBCs entities, a characterisation of
basal-like tumours at the genomic and transcriptomic
levels is an urgent need. In this contribution, we aim
at identifying markers associated with patients’ survival
using larger breast cancer cohorts from the Molecular
Taxonomy of Breast Cancer International Consortium
(METABRIC) [32] and Research Online Cancer Knowl-
edgebase (ROCK) [33]. Through the determination of
this signature, our objective is to stratify 351 tumours
into basal-like subgroups, with varying clinical features
and survival outcomes, and further describe each of
them. Accordingly, we plan to explore the microarray
data – including gene (mRNA) and microRNA (miRNAs)
expression values, and copy number aberration (CNA)
measurements – to expand themolecular characterisation
of BLBCs, which to our knowledge has not yet been per-
formed. The assessment of more comprehensive profiles
of BLBCs is relevant for defining groups-at-risk in clini-
cal settings and, more importantly, for improving therapy
response.
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Methods
Breast cancer data sets
The METABRIC genomic and transcriptomic data
sets were downloaded from the European Genome-
Phenome Archive (EGA) (http://www.ebi.ac.uk/ega),
under the accession numbers EGAS00000000083 and
EGAS00000000122. These publicly available collections
contain genotyping (Affymetrix SNP 6.0), log2 nor-
malised gene expression (Illumina_Human_WG-v3)
and miRNA expression (Agilent ncRNA 60k) arrays for
over 2000 breast tumours and 144 control (non-tumour)
breast samples [32]. The original METABRIC study was
approved by the ethics Institutional Review Boards in the
UK and Canada (Addenbrooke’s Hospital, Cambridge,
United Kingdom; Guy’s Hospital, London; Nottingham;
Vancouver; Manitoba). Further analysis on this data
was approved by the Human Research Ethics Commit-
tee (HREC) at the University of Newcastle, Australia
(approval number: H-2013-0277).
The METABRIC cohort has a comprehensive descrip-
tion of patients long-term clinical and pathological out-
comes. Tumour samples were assigned to a breast cancer
subtype (luminal A, luminal B, HER2-enriched, normal-
like, or basal-like) using an ensemble learning approach
[34], employing the set of 50 genes defined by Parker
et al. (2009) [22]. This approach has been previously
shown to improve the samples classification and subtypes’
assignement in METABRIC data set, and has revealed
more consistency in terms of clinical features and sur-
vival outcomes [34]. Based on these labels, a subset of 250
basal-like tumours was selected for analysis in this study.
For training and test purposes, this subset was randomly
split into two sets of equal size (125) to avoid possible bias
from the original cohort. The sets are hereafter referred to
as the training and validation sets.
For additional validation across platforms, we used the
ROCK data set obtained at Gene Expression Omnibus
(GEO) (http://www.ncbi.nlm.nih.gov/geo/), under data
source number GSE47561 [33, 35]. This data set integrates
ten different studies (GSE2034, GSE11121, GSE20194,
GSE1456, GSE2603, GSE6532, GSE20437, GSE7390,
GSE5847 and E-TABM-185) performed on the Affymetrix
HG-U133A technology. The compiled matrix contains
log2 RMA renormalised gene expression values for 1570
tumour samples, 101 of which are of basal-like subtype.
The ROCK data set includes representative information
for survival analysis, however, it lacks standard clinico-
pathological data which therefore has not been considered
in this study.
Probe selection approach
Since the first aim of our study is to identify markers driv-
ing survival among basal-like patients, we designed a fil-
tering technique to select a representative probe signature
and reduce the bias arising from the high number of
probes (48,803) and low number of samples (125) in the
training set. We defined two relevant criteria to select
probes, which are involved in tumour initiation and/or
progression, and are also correlated to survival, as detailed
below.
The Differential filter [36] was employed to select
probes exhibiting distinct expression levels between
tumours and controls. The underlying assumption is that
probes truly correlated with breast cancer are linked to
genomic changes or variations from healthy to cancer-
ous tissue. We applied the Differential filter to each of
the 48803 probes to test their separation power between
the 125 tumours and 144 controls. This filter tests for
three feasible cases: the expression levels in tumours are
(a) lower than, (b) higher than, or (c) lower and higher
than in control samples. The last case refers to genes that
are up-regulated in some tumours and down-regulated in
others, while the expression levels of controls lie between
these two groups. To calculate a p-value for this case, we
mirrored all expression levels on one side with respect
to the mean value of controls. The separation power of
each probe was defined as the minimal Wilcoxon test p-
value calculated for the three cases. To determine the
number of probes passing the Differential filter, we plot-
ted the ordered log10-normalised p-values against the
corresponding probe ranks. The threshold was set approx-
imately at the point of the highest curvature of this func-
tion. This threshold is based on the naturally emerging
systemic behaviour and does not require an external def-
inition. Probes passing this filter are referred to as the
differential probe set.
The Survival filter [36] was used to further identify
probes for which the expression levels are associated with
patients’ survival. This filter employs the Kaplan-Meier
estimator to compute the survival probabilities. The strat-
ification power of each probe is calculated using the Log-
rank test applied to two groups of samples corresponding
to quantiles with the lowest and the highest expression
values, respectively. We defined these quantiles by order-
ing all samples by their expression values of a probe and
selected samples in the first and last thirds (the quantile
from 0 to 33% in the relatively under-expressed and from
67 to 100% in the relatively over-expressed group). This
analysis was performed in R using the package survival
[37]. Since the survival information is not provided for
all samples, this calculation was based on 115 basal-like
tumour samples (from the total of 125) in the METABRIC
training set. To determine the number of probes passing
the Survival filter we used a similar threshold definition
as for the Differential approach, i.e. by ordering the log10-
normalised p-values that emerged from the Log-rank
test. These probes are further referred to as the survival
probe set.
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Clustering basal-like tumour samples
The second aim of our study is to identify and charac-
terise basal-like subgroups with varying disease outcomes.
To this end, we performed a hierarchical clustering of
samples based on the previously defined survival probe
set. This procedure exploits the assumption that probes
showing most variations in expression and co-expression
among each other are involved in similar biological mech-
anisms and have a high impact on the groups delineation.
To calculate the dissimilarity between the 115 samples
from the METABRIC training set, for which the sur-
vival information is provided, we used the square root of
the Jensen-Shannon divergence [38–40]. We then gener-
ated the hierarchical clustering with the Ward’s criterion
that minimises the variance within clusters, using the R
package stats [41].
We further examined which probes from the survival
probe set contribute the most to the separation of basal-
like subgroups using the Wilcoxon test. We then ordered
the log10-normalised p-values to determine the probes
that significantly differentiate between the subgroups by
using the same threshold criterion as for the Differential
filter. The purpose of this procedure is to refine the probes
that best segregate basal-like subgroups of distinct disease
outcome. These probes are further referred to as the probe
signature and expose striking genes and cell mechanisms
involved in the subgroups differentiation.
Validation across data sets
The basal-like entities were first matched to the
METABRIC validation set by means of centroids com-
puted based on the previously defined probe signature.
Samples in this data set were then assigned to a subgroup
according to the minimal Euclidean distance to a centroid.
An external validation was conducted on the ROCK
data set, for which the centroids were mapped across
technologies – from Illumina to Affymetrix – using
the gene annotation packages hgu133a.db and illumi-
naHumanv3.db [42] in R Bioconductor. Since the mRNA
level measurement and normalisation differ between
METABRIC (Illumina) and ROCK (Affymetrix) data sets,
we standardised the calculated centroid absolute values
with respect to the average expression levels computed for
all basal-like samples. This procedure is depicted in Eq. 1,
where si,j is the expression value of probe j for sample i,
andN is the total number of basal-like samples (N is equal








Following the centroids’ normalisation, an analogous
transformation of Affymetrix gene expression values was
necessary to enable their direct application. Thus, we
applied the same formula (Eq. 1) to the ROCK data set,
where the number N of total samples is 101. The assign-
ment to subgroups was based on the minimal Euclidean
distance to a standardised centroid.
Network analysis
With the purpose to identify key players within the probe
signature and their relation to each other, we generated
and plotted a network graph using the Minimum Span-
ning Tree (MST) [43]. The distance d(x, y) between two
probes x and y were defined as d(x, y) = 1 − |ρS(x, y)|,
where ρS(x, y) is the value of the Spearman correlation
between the probe expression calculated for 125 tumour
samples from the training set. To quantify the network
analysis, we computed the betweenness centrality and
node degree of each node (probe) using the package
igraph [44] in R.
Generally, nodes with high betweenness centrality and
degree values represent potential key players within the
network. With regards to the centrality values, the most
representative entities are highly connected to the rest of
the tree; leaf-nodes have a betweenness centrality value of
0, while the most traversed nodes are assigned with the
highest values (normalised up to 1). Node degree, on the
other hand, is indicative of the number of direct neigh-
bours of a node. Thus, probes with high degrees are also
central (representative) for local groups with a relatively
strong probe co-expression.
MicroRNA differential expression
To uncover the miRNAs differentiating the most between
the basal-like subgroups, we applied the Wilcoxon test
to expression values of each of the 853 probes avail-
able in the METABRIC data set. We considered those
miRNAs with the emerging p-values smaller than 0.01
in both training and validation sets, as relevant for the
separation between the subgroups. Both data sets were
used due to the limited number of samples (146 in total)
for which the miRNA expression profiles were provided.
The miRNA probes were further investigated for possi-
ble target genes within the probe signature using R Bio-
conductor (RmiR.Hs.miRNA [45]) across five databases:
miRBase, TarBase, PicTar, MirTarget2 and miRanda. For
the miRNA and gene annotation we used the pack-
ages hgug4112a.db [46] and illuminaHumanv3.db [42],
respectively.
Copy number aberration profiles
To quantise the CNA information we employed the cyto-
bands defined in the hg18 data base that corresponds to
the METABRIC platform. Aberrations were divided into
two categories: losses (originally denoted as homozygous
and heterozygous deletions) and gains (gains and amplifi-
cations). For each basal-like subgroup we then calculated
the occurrence rates of gains and losses per cytoband,
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and applied the Binomial test to examine the hypothesis
that the CNA distributions were the same among patient
subgroups.
We further calculated the Percent Genome Altered
(PGA) for each of the basal-like subgroups and applied the
Wilcoxon test to these rates to obtain a significance value
of the difference between them. The aim of this approach
is to identify stable/unstable genome profiles associated
with the patient subgroups defined by our probe signature
and to statistically describe whether they are consistently
diverging.
Results
Survival-related probes defining basal-like breast cancer
subgroups
With the application of theDifferential and Survival filters
in the METABRIC training set – as detailed in “Methods”
– we identified 15000 and 400 probes related to can-
cer initiation and/or progression, and patients survival,
respectively. The corresponding probes in the differential
probe set with distinct expression levels between tumours
and controls showed significant p-values ranging from
2.36 · 10−45 to 1.53 · 10−7. The reduced number of probes
in the survival probe set related to the individual survival
had significant p-values ranging from 1.11 · 10−4 to 0.038.
These probes, ultimately, comprise a representative sig-
nature driving the outcome of basal-like patients in the
METABRIC breast cancer cohort.
The hierarchical clustering of 115 basal-like samples
based on the survival probe set has revealed two major
subgroups: Basal I and Basal II (Additional file 1: Figure
S1). A separation into more than two subgroups – in the
next and subsequent hierarchical divisions in the dendro-
gram – was not supported due to the high similarity of
subgroups in terms of their molecular profile and clin-
ical outcome. The application of the Wilcoxon test has
defined the probe signature containing the top 80 probes,
with significant p-values ranging from 1.75 ·10−13 to 3.77 ·
10−4, differentiating the most between the two basal-like
groups at the transcriptomic (mRNA) level. A heat map
of the 80-probe signature for the training set is plotted in
Fig. 1, where samples are ordered within each subgroup
by their Euclidean distance to the corresponding centroids
(Additional file 2: Tables S1, S2 and S3).
To characterise the 80-probe signature with respect to
their cellular function, we clustered the probes by their
mutual correlation into three groups (Table 1) – G1, G2
and G3 – and annotated using the Database for Anno-
tation, Visualization and Integrated Discovery (DAVID)
(Additional file 3: Tables S4, S5 and S6). This analysis
revealed that G1 probes are strongly associated with cell
cycle control and cell division; they are over-expressed in
Basal II subgroup. G2 showed relation to immune system
and inflammatory response. Remarkably, the expression
levels of G2 probes in Basal II are similar to that observed
in controls, but much higher in Basal I, suggesting an
intratumoral infiltration by lymphocytes in this subgroup.
In the last group, G3, probes indicate an association (not
significant) with metal-binding processes; they are under-
expressed in Basal II when compared to Basal I and
control samples.
The betweenness centrality and node degree analysis of
the 80-probe signature (Fig. 2) further outlined impor-
tant genes differentiating between Basal I and Basal II
subgroups (Table 1). The genes with the highest cen-
trality values (B ≥ 0.1) in G1 are PSMG3, HJURP,
BEND3, C10orf2, TPX2, RRP12 and DNMT3B; in G2,
CXCR6, HCST, C3AR1, GBP4, LY96, ANKRD22, FPR3
and FCGR2A; and in G3, CTSK. Within this set, the genes
HJURP, RRP12, DNMT3B, CXCR6, HCST, C3AR1, FPR3
and CTSK also showed high node degree values (ND
≥ 4), representative for probe co-expression, corroborat-
ing with their key role on the differentiation of basal-like
carcinomas.
Basal I and Basal II validated across independent data sets
andmicroarray platforms
The quality of the 80-probe signature was evaluated using
centroids calculated for the training set and applied to
the METABRIC and ROCK validation sets. In ROCK, 55
annotated probes matched from Illumina to Affymetrix
and were validated across the microarray platforms. The
corresponding heat maps, in Fig. 1, showed the existence
of two main basal-like subgroups, Basal I and Basal II, in
bothMETABRIC and ROCK validation sets. The two sub-
groups are consistent with regards to the population size
and mRNA expression levels (in G1, G2 and G3) and fur-
ther support the quality of the 80-probe signature. The
definition of more than two subgroups in the hierarchi-
cal clustering would lead to the separation of entities with
highly similar molecular profiles.
Clinical features and survival outcomes supporting the
basal-like subgroups
The analysis of clinicopathalogical markers revealed a
significant correlation between the basal-like subgroups
defined in this study and tumour histology (Invasive Duc-
tal Carcinoma versus medullary type), tumour size and
p53 status (Table 2). According to histological classifica-
tion, the medullary type is more common among Basal
I patients. On the other hand, the Basal II subgroup is
characterised by larger tumours (in size) and a higher fre-
quency of p53 mutation. Clinical features, such as age,
menopausal status (MS), grade, Nottingham Prognostic
Index (NPI) and lymph nodes, did not show statistically
significant variations across the two basal-like subgroups.
The survival analysis revealed significant differences in
patients’ outcome between Basal I and Basal II. Basal I
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Fig. 1 Heat map of the 80-probe signature in METABRIC training set. This figure displays 80 survival-related probes clustered by their mutual
correlation. Samples in each basal-like subgroup are ordered by their overall rank and the expression values are normalised across individuals. The
subgroups in the METABRIC validation set were defined using centroids computed in the training set. In the ROCK data set, 55 Affymetrix probes
matched the 80 Illumina signature; samples in this data set are ordered by their overall rank within each subgroup
showed a better prognosis in comparison to Basal II in all
data sets (Fig. 3), with the Log-rank test p-values of 0.0097,
0.017 and 0.043 for the METABRIC training, validation
and ROCK data sets, respectively.
MicroRNAs differentially expressed between Basal I and
Basal II subgroups
We identified 17 miRNAs and 2 putative probes differ-
entially expressed between the two basal-like subgroups
(Table 3), with the Wilcoxon test p-values smaller than
0.01 in both METABRIC data sets (Additional file 4:
Tables S7, S8 and S9). The probes hsa-miR-155, -342-
5p and -150 showed the lowest p-values and an over-
expression in Basal I, when compared to Basal II and
control samples. The transcripts hsa-miR-19b-1*, -17* and
-200c*, on the other hand, were over-expressed in Basal
II tumours relative to Basal I and controls. The expres-
sion levels of all probes are depicted in Fig. 4. Additionally,
the identifiedmiRNAs werematched against the 80-probe
signature revealing a set of 50 gene-targets across five dis-
tinct databases, as listed in Table 4 and further detailed
for Basal I and Basal II in Additional file 4: Tables S7,
S8 and S9. Among the gene-targets, C10orf2, HSD11B1,
EGR2, FBXL5, CLEC7A, DNMT3B, FMO1, CTSK and
PYHIN1were present in at least two databases. A compar-
ison between miRNA and gene expression levels across
subgroups showed significant correlations of hsa-miR-
142-5p and RASSF5, hsa-miR-142-5p and TIMP3, hsa-
miR-150 and MIAT, and hsa-miR-22 and TIMP3 in both
Basal I and Basal I.
Copy number aberration profiles further differentiating
basal-like subgroups
The integrated analysis of CNA has revealed an increasing
number of genomic changes from Basal I to Basal II sub-
group (Fig. 5) and uncovered cytobands with significant
aberrations (binomial test p-values below 0.15) in both
METABRIC training and validation sets (Table 5). Accord-
ingly, critical gains/amplifications were detected on chro-
mosomes 1q, 3q, 8q, 10p and 17q, and losses/deletions on
4q, 5q, 8p, Xp and Xq. Several of these aberrations have
been previously associated with primary breast tumours
and cell lines in BLBCs and/or TNBCs studies [20, 47–50].
Notably, the percent of the genome being altered in the
training set for Basal I was 2.74% for gains and 0.23% for
losses; in Basal II it was 9.06 and 1.03%, respectively. The
Wilcoxon test showed significant heterogeneity among
the subgroups for the gains (p-value = 1.91 · 10−6) and
for losses (p-value =9.55 · 10−4). The same pattern was
observed in the validation set for Basal I (3.58% for gains
and 0.13%) and Basal II (10.46% for gains and 2.54%), also
highly significant (Wilcoxon test: p-value = 1.11 · 10−6 for
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Table 1 The 80-probe signature related to survival
Gs Gene Probe ID B ND
G1 C10orf2 ILMN_1701243 0.17 3
RRP12 ILMN_1767253 0.12 4
CD24 ILMN_2060413 0 1
SURF6 ILMN_1778032 0 1
GPATCH1 ILMN_1655625 0.03 2
CEL ILMN_1723418 0 1
LOC641765 ILMN_1692198 0 1
DNMT3B ILMN_2328972 0.1 4
MIS18A ILMN_1712386 0 1
DSN1 ILMN_1715905 0.03 2
TPX2 ILMN_1796949 0.14 3
HJURP ILMN_1703906 0.42 5
CAD ILMN_1810992 0 1
BEND3 ILMN_2375032 0.21 3
EIF2AK1 ILMN_2156267 0.07 2
PSMG3 ILMN_1802627 0.47 3
MXD3 ILMN_1711904 0 1
PSRC1 ILMN_2315964 0 1
ASPSCR1 ILMN_1660749 0.05 2
PRKCSH ILMN_1777794 0.03 2
LOC650803 ILMN_1803510 0.05 2
KCTD15 ILMN_1786326 0 1
RBFA ILMN_1736130 0 1
STK25 ILMN_1668090 0.03 2
G2 PYHIN1 ILMN_1742026 0.05 3
THEMIS ILMN_1684040 0 1
PCED1B ILMN_1712431 0.03 2
PTCRA ILMN_2091920 0 1
HCST ILMN_2396991 0.57 6
LY96 ILMN_1724533 0.45 3
CASP4 ILMN_1678454 0 1
SNTB1 ILMN_1793410 0 1
GBP4 ILMN_1771385 0.46 2
DOK2 ILMN_1791211 0 1
GM2A ILMN_2221046 0 1
FPR3 ILMN_2203271 0.17 4
C3AR1 ILMN_1787529 0.47 7
FCGR2A ILMN_1666932 0.12 2
CCR1 ILMN_1678833 0 1
LOC647108 ILMN_1774206 0.03 2
CLEC12A ILMN_2403228 0 1
CLEC12A ILMN_1663142 0.03 2
ADORA3 ILMN_1730710 0 1
CLEC7A ILMN_1700610 0.03 2
LOC650799 ILMN_1715436 0 1
MIAT ILMN_1864900 0 1
IKZF3 ILMN_2300695 0 1
ANKRD22 ILMN_2132599 0.45 2
AIM2 ILMN_1681301 0.03 2
Table 1 The 80-probe signature related to survival (Continuation)
Gs Gene Probe ID B ND
IL2RA ILMN_1683774 0 1
MARCH1 ILMN_2094942 0.05 3
LAP3 ILMN_1683792 0 1
GPR65 ILMN_2232121 0.03 2
GPR65 ILMN_1734740 0.05 2
FAM26F ILMN_2066849 0 1
CXCL11 ILMN_2067890 0 1
NFS1 ILMN_1761314 0.05 2
CXCR6 ILMN_1674640 0.68 10
RASSF5 ILMN_2362902 0.07 2
NAPSB ILMN_1723043 0.05 3
IKZF1 ILMN_1676575 0 1
PTPN22 ILMN_1715885 0 1
PTPRC ILMN_1653652 0.07 3
PTPN22 ILMN_2246328 0 1
G3 RPL36AL ILMN_2189936 0 1
GARNL3 ILMN_1779347 0 1
PNPLA4 ILMN_1664348 0 1
SH3BGRL ILMN_1702835 0.03 2
HS.576380 ILMN_1848030 0 1
FMO1 ILMN_1684401 0 1
CTSK ILMN_1758895 0.1 4
EGR2 ILMN_1743199 0 1
CLEC1A ILMN_1691339 0 1
HSD11B1 ILMN_2389501 0.03 2
CEBPA ILMN_1715715 0 1
TIMP3 ILMN_1701461 0.03 2
FBXL5 ILMN_1673370 0 1
SCARNA9 ILMN_1805064 0 1
PPM1M ILMN_1657810 0.05 3
DOCK6 ILMN_1801226 0 1
The 80 annotated Illumina probes distinguishing between basal-like subgroups are
listed in this table. The official gene symbol (Gene), from UCSC Genome Browser,
and Illumina probe IDs (Probe ID) are provided for each probe group (Gs), in the
same order as shown in Fig. 1. This table also contains the betweenness centrality (B)
and node degree (ND) values calculated for each probe in the basal-like training set
gains and p-value = 5.37 · 10−6 for losses). The increasing
genome instability represented by increasing PGA, plot-
ted in Fig. 5, occurred consistently, from Basal I to Basal
II, with the decreasing rates of patients’ survival.
Discussion
Survival-related probes defining the molecular signature
of basal-like breast cancer subgroups
The basal-like subgroups defined in this study show
distinct patterns in terms of tumour molecular pro-
files, clinicopathological features and patients survival
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Fig. 2Minimum Spanning Tree of the 80-probe signature. The MST graph was generated for the 80 probes in the training set. Only probes with
high correlation values between their expression levels are connected to a network. The size of each node is proportional to the computed node
degree value (number of connections). The colour of each node is reflective of the betweenness centrality value ranging between low (light pink)
and high (red)
outcomes. The characterisation of BLBCs, considering the
two major entities Basal I and Basal II, is supported by the
identification of the 80-probe signature, validated across
Illumina and Affymetrix platforms in the METABRIC
and ROCK cohorts. The importance of this signature,
genes and gene-families, is defined by their functional-
ity for each set: G1, G2 and G3. The annotated probes
revealed their association with cell cycle and cell division
components, immune/inflammatory regulation andmetal
binding, respectively, and defined Basal I (Immune Active)
and Basal II (High Proliferative) subgroups. In Basal I, the
over-expression of G2 probes suggests an immune activa-
tion and lymphocytic infiltration, particularly regulating
tumour growth and patients’ survival. This role has been
previously associated with a better prognosis and therapy
response [51], and has the potential to stratify basal-like
breast cancers. On the other hand, the over-expression of
G1 cell cycle-related genes and under-expression of G3
metal binding genes in Basal II impact on cell prolifera-
tion rates and energy metabolism. In this case, the cells
reproduce at a rate far beyond the common bounds of a
controlled cell cycle, concomitantly with other molecular
changes in metabolic processes.
The G1 genes PSMG3, HJURP, BEND3, TPX2, RRP12
and DNMT3B exhibited the highest centrality values and
were over-expressed in the Basal II subgroup. HJURP, for
instance, plays a central role in the maintenance of newly
replicated centromeres and mitotic regulation. Increased
levels of this gene in primary tumours and breast can-
cer cell lines have been previously correlated to decreased
disease-free and overall survival [52]. Also involved in the
mitotic spindle assembly, TPX2, when over-expressed, has
been associated with proliferation networks and metas-
tasis enhancement, holding a prognostic value for breast
cancer patients [53]. Additionally, the hyperactivity of the
DNA methyltransferase enzymes, or the over-expression
of DNMT3B, has been further reported in BLBCs and
TNBCs, where the hypermethylation events were more
frequent than in other breast cancer subtypes [54]. Hyper-
methylated tumours also presented decreased levels of
regulatory miRNAs, including hsa-miR-29a and -29b. In
particular, the under-expression of hsa-miR-29c has been
marked as characteristic of BLBCs, segregating them into
two subsets [55], which has been supported by our find-
ings. More studies, however, are required to investigate
the biological role of other representative genes, such as
PSMG3, BEND3 and RRP12 in G1.
A number of G2 genes are key regulators of the
basal-like tumorigenesis, such as CXCR6, HCST, C3AR1,
GBP4, LY96, ANKRD22, FPR3 and FCGR2A. These genes
show the highest betweenness centrality and node degree
among tumours, and appeared over-expressed in Basal I.
In other reports, the CXCR6 over-expression has been
linked to TNBCs, with distinct roles in autoimmunity and
cancer [56]. The co-expression of CXCR6 and CXCL16,
a chemokine ligand and receptor, has been associated
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Table 2 Clinicopathological information for patients in the
METABRIC data set
Training set Validation set
Basal I Basal II Basal I Basal II
Age [years]
≤ 40 7 18 4 17
41 to 50 11 18 10 21
51 to 60 8 20 9 16
> 60 9 24 13 35
mean 50.6 52.5 54.7 54.1
p-value 0.46 0.8
MS
Pre/post 18/17 36/43 15/21 37/52
Pre/post (%) 51.4% 45.6% 41.7% 41.6%
p-value 0.31 1
Size [cm]
≤ 2 cm 15 30 17 32
> 2 cm 20 50 19 55
Mean 23.5 30.6 22.1 29.6
p-value 0.01 0.005
Grade
Grade 2 2 8 5 3
Grade 3 33 71 30 85
Na 0 1 1 1
Mean 2.9 2.9 2.9 3
p-value 0.4 0.092
NPI
≤ 2.4 0 1 1 1
2.4 to 3.4 1 6 3 2
3.4 to 5.4 28 62 27 77
> 5.4 6 11 5 9
Mean 4.7 4.6 4.5 4.6
p-value 0.43 0.7
Lymph Node
Neg/pos 16/19 37/43 17/19 47/42
Neg/pos (%) 45.7% 46.2% 47.2% 52.8%
p-value 1 0.34
Histology
ILC 0 2 0 1
IDC 28 70 23 83
IDC-med 7 5 9 3
Others 0 3 4 2
p-value 0.001 5.4 · 10−8
p53
Mut/wild 1/15 11/14 2/11 12/17
Mut/wild (%) 6.25% 44% 15.4% 41.4%
p-value 1.1 · 10−7 7 · 10−4
Population size
35 80 36 89
The clinicopathological features described are: Age in years, menopausal status
(MS), tumour Size in cm, tumour Grade [1–3], Nottingham Prognostic Index (NPI),
Lymph Node invasion, histopathological classification (Histology) and p53 status, for
Basal I and II subgroups in the METABRIC discovery and validation sets. In all cases,
the p-value indicates the significance of the difference between Basal I and II
subgroups. For numerical variables (Age, Size, Grade, and NPI) it was calculated
using the ANOVA on ranks; for the categorical (MS, Lymph Node, Histology, p53), a
binomial test was used. Population sizes for each group are indicated in the last row.
Tumour histology is as follows: IDC=Invasive Ductal Carcinoma, ILC=Invasive
Lobular Carcinoma, IDC-med=Medullary Carcinoma, and others include tubular,
mucinous and phyllodes tumours
with inflammatory response and cell migration [57, 58]. In
addition, high levels of HCST [59, 60], C3AR1 [61], GBP4
[62], LY96 [63], ANKRD22 [64], FPR3 [65] and FCGR2A
[66], have also been related to immune activation and/or
inflammatory response in tumours; however, their role in
basal-like breast malignancies are yet to be uncovered. In
our study, the increased expression levels of these probes,
among others genes in the signature, has brought new
insights on the basal-like tumour origin and progression,
and Basal I and Basal II differentiation.
Standard clinical variables such as tumour size, his-
tology and p53 status have also corroborated with the
existence of the two basal-like subgroups. Basal I showed
the highest frequency of medullary type, whereas Basal
II exhibits the largest average of tumour size and high-
est frequency of p53 mutation. The interpretation of
these features, in practice, support the better outcome of
patients within Basal I subgroup, when compared to Basal
II. Patients’ age, post-menopausal status, tumour grade,
NPI and lymph node invasion, on the other hand, are of
a limited value for distinguishing the subgroups. Most of
these variables reflect the overall tumour aggressiveness
and the subtype poor prognosis.
MicroRNA expression levels differentiating Basal I from
Basal II subgroup
This work is the first instance of miRNA data cover-
age yielding the analysis of basal-like subgroups, which
includes patients with matched genomic, transcriptomic
and long-term survival data [67]. The miRNAs have
showed an important value for differentiating Basal I (15)
and Basal II (4). In Basal I, hsa-miR-361-3p, -342-3p, -
140-3p, -34a, -22, -142-5p, -142-3p, -155, -342-5p, -150,
-29c and -29a presented increased expression relative to
Basal II. Overall, hsa-miR-361-3p has been found over-
expressed in TNBCs with respect to other subtypes and
healthy controls [68]; and used to discriminate BRCA1/2
mutation carriers and non-carriers tumours [69]. Greater
levels of this miRNA, however, have been associated with
a protective value in tumour progression [70] and further
linked to inflammatory response [71]. In line with our
findings, these results contain additional information for
the better understanding of basal-like subgroups. Addi-
tionally, high levels of hsa-miR-342-5p [72, 73] and -34a
[74, 75] have been correlated to breast cancer decreased
recurrence and increased survival; whereas low levels have
been associated with cell death inhibition and therapy
resistance. The hsa-miR-22 [76, 77] and members of the
hsa-miR-29 family (-29a, -29b and -29c) [55, 78] – previ-
ously identified as tumour suppressors – have also been
implicated in increased survival [78] and pointed out as
promising prognostic biomarkers [77, 79].
In Basal II, hsa-miR-19b-1, -17 and -200c presented
higher expression levels relative to Basal I and control
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Fig. 3 Survival curves in METABRIC and ROCK data sets. The survival analysis was performed using the Kaplan-Meier estimator. The grey line shows the
disease specific survival of all basal-like samples in the training and validation sets, respectively. Basal I subgroup is shown in turquoise, and Basal II in
coral. Ticks represent sensors of patients who are alive and drops denote deaths. Survival curves based on the last 10 observations are plotted in dash
Table 3 MicroRNAs differentiating between basal-like breast
cancer subgroups
miRNA Probe ID p-value
hsa-put-miR-92597 CRINCR2000005427 2.8 · 10−4
hsa-miR-361-3p A_25_P00012305 2.8 · 10−4
hsa-miR-342-3p A_25_P00012357 4 · 10−4
hsa-miR-140-3p A_25_P00012177 1.3 · 10−4
hsa-miR-34a A_25_P00012086 4.9 · 10−3
hsa-miR-22 A_25_P00010204 6.3 · 10−3
hsa-miR-142-5p A_25_P00014844 2 · 10−4
hsa-miR-142-3p A_25_P00011016 2.2 · 10−3
hsa-miR-155 A_25_P00012271 6.3 · 10−6
hsa-miR-342-5p A_25_P00012354 2 · 10−7
hsa-miR-150 A_25_P00014847 8.7 · 10−6
hsa-put-miR-4391 CRINCR2000005084 1.2 · 10−4
hsa-miR-29c A_25_P00012274 6.7 · 10−3
hsa-miR-29c* A_25_P00013484 5.6 · 10−4
hsa-miR-29a A_25_P00012013 4.8 · 10−3
hsa-miR-19b-1* A_25_P00013163 5.3 · 10−4
hsa-miR-17* A_25_P00013151 5 · 10−4
hsa-miR-17 A_25_P00013841 1.9 · 10−3
hsa-miR-200c* A_25_P00013469 1.8 · 10−4
The miRNAs differentially expressed in Basal I and II subgroups are listed in this
table, with the corresponding p-value in the METABRIC training set. Probes above
the mid-line indicate the miRNAs over-expressed in Basal I, while those below are
over-expressed in Basal II. Probe IDs correspond to the Agilent platform
samples. Tumour cells with enhanced expression of hsa-
miR-19 (-19a and -19b-1) have been shown to trigger
epithelial-mesenchymal transition [80]. Notably, mem-
bers of the hsa-miR-200 family have been described as
major regulators of this biological process. High levels
of hsa-miR-200c and -200b have been observed in circu-
lating tumour cells from patients with metastatic breast
cancers [81], indicating the prognostic significance of this
biological marker [82, 83]. Consistent with these obser-
vations, our results demonstrated the recurrent over-
expression of hsa-miR-19b-1 and -200c in Basal II, with
the worst disease outcome among the two basal-like sub-
groups. Ultimately, high levels of hsa-miR-17 has been
commonly detected in TNBCs [84], associated with cell
migration in vitro and metastasis in vivo [85].
The above described miRNAs matched 50 gene-targets
from the 80-probe signature. In our study, hsa-miR-200c*
and -29c have been associated with HJURP expression
levels in G1, hsa-miR-19b-1* with CXCR6 in G2, and hsa-
miR-17 with CTSK in G3, which are among the most
important genes in the signature. None of these asso-
ciations, however, have been reported in the literature.
On the other hand, studies have demonstrated hits on
the gene regulation between hsa-miR-142-5p and CD24
[86], hsa-miR-29 and DNMT3B [87, 88], hsa-miR-142-3p
and EGR2 [89], hsa-miR-150 and EGR2 [90], hsa-miR-34a
and IKZF3 [91], hsa-miR-150 and MIAT [92], hsa-miR-
342-3p and PSMG3[93, 94], hsa-miR-17 and TIMP3 [95].
Our results further suggested an important correlation
between miRNAS and gene expression values in both
Basal I and Basal II, identified by this in silico approach.
These and other correlations are, however, highly com-
plex and not fully understood. Additional analysis using
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Fig. 4 The box plot of miRNAs differentiating between Basal I and Basal II subgroups. The image shows the expression levels of 19 miRNAs across
basal-like subgroups and other samples in the METABRIC data set. Basal I is shown in turquoise, Basal II in coral, controls in grey and all breast cancers
in yellow
in vitro and in vivo models are required to validate our
achievements.
Genomic aberrations further characterise Basal II and Basal
I subgroups
Basal-like and triple-negative tumours exhibit the
highest frequencies of genomic gains and losses in
comparison to other breast cancer subtypes [50].
Significant aberrations observed in this study confirmed
the genomic instability among basal-like and further
differentiated the two subgroups. The most common
aberrations delineating Basal II, with respect to Basal
I, occurred on the chromosomes 1, 3, 4, 5, 8, 10, 17
and X.
Table 4 MicroRNAs and corresponding target genes
miRNA Target
hsa-miR-361-3p C3AR1, CEBPA, GM2A,MIAT, SURF6, TIMP3
hsa-miR-342-3p MXD3, PSMG3, PTCRA, PTPRC, TIMP3
hsa-miR-140-3p C10orf2, CXCL11, KCTD15, PNPLA4, PRKCSH, RRP12, STK25
hsa-miR-34a CXCL11, DSN1, FCGR2A, GPR65, IKZF3, PNPLA4
hsa-miR-22 DOK2, GM2A, HSD11B1,MXD3, PNPLA4, STK25, TIMP3
hsa-miR-142-5p C10orf2, CD24, CEBPA, EGR2, FBXL5, FPR3, HSD11B1, RASSF5, TIMP3
hsa-miR-142-3p CD24, EGR2, PNPLA4, SH3BGRL
hsa-miR-155 PSRC1, RBFA
hsa-miR-342-5p ASPSCR1, CASP4, IKZF1, PSRC1
hsa-miR-150 CCR1, EGR2, FBXL5,MIAT
hsa-miR-29c CLEC7A, DNMT3B, FCGR2A, FMO1, KCTD15,MIAT, TPX2
hsa-miR-29c* GARNL3, HJURP,MIS18A
hsa-miR-29a CLEC7A, DNMT3B, FCGR2A, FMO1, KCTD15,MIAT, TPX2
hsa-miR-19b-1* CXCR6, FCGR2A, HSD11B1,MXD3
hsa-miR-17 AIM2, BEND3, CEL, CTSK , EGR2, FBXL5, PNPLA4, PYHIN1, SNTB1, TIMP3
hsa-miR-200c* DOK2, HJURP, IL2RA, PSRC1, RRP12
The differentially expressed miRNAs and corresponding target genes within the 80-probe signature are listed in this table. The matching targets appeared in at least one of
the five databases:miRBase, TarBase, PicTar,MirTarget2 andmiRanda. Target genes that were present in at least two databases are underlined
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Fig. 5 Copy number aberration defined for basal-like subgroups in the METABRIC data set. a The CNA information is plotted for 23 chromosomes
(including the X chromosome); the percentage of the population showing amplification/gain (Amp) or deletion/loss (Del) were calculated for each
cytoband. b The boxplots represent the PGA computed for each METABRIC data set
Gains in 1q, 3q, 8q, 10p and 17q have been identi-
fied in our analysis and previously reported in triple-
negative tumours [48–50]. Overall, gains on chromosome
1q are the most frequent CNAs detected in breast
carcinomas and are normally complex and discontinu-
ous [96, 97]. Amplicons of 1q, 8p and 10p have been
also described. These amplicons have contributed to the
molecular understanding of this disease and, specially,
of basal-like intrinsic subtype [98]. For instance, amplifi-
cations in 8q21 have been associated with high tumour
grade, high levels of Ki67 and other proliferation mark-
ers, including MYC, MDM2 and CCND1 [99]. Gains in
10p have further differentiated triple-negative cancers
[48], and in 17q25 have distinguished BRCA1-mutated
tumours [100].
Losses in 4q, 5q, 8p, Xp and Xq have been defined as
key aberrations within basal-like tumours in our analysis
and among other breast cancer studies [20, 49]. Frequent
losses in 4q and 5q in BRCA1-mutated tumours have
distinguished them from sporadic neoplasms. In particu-
lar, the loss in 5q has impacted the expression of several
BRCA1-dependent genes involved in DNA repair, such as
RAD17 and RAD51 [101]. High incidence rates of gains in
5q14 have also been associated with a poor prognosis in
BLBCs [102]. Other evidence suggests that aberrations on
the X chromosome are common to both BRCA1-mutated
and sporadic tumours [103].
Overall, these aberrations yielded an additional charac-
terisation of Basal I and Basal II. The increasing PGA, or
genome instability, from one subgroup to the other com-
plemented the 80-probe signature via the transcriptomic
assessment, which is still considered more representa-
tive of cellular processes at the proteomic scale [104].
Although the identified CNA did not show a direct cor-
relation with the 80 probes’ expression levels, generally
it may lead to widespread disruptions beyond the pro-
posed signature. Ultimately, the above described gains and
losses in cytobands – supported by a range of distinct
approaches in the literature – further corroborate the dif-
ferentiation of basal-like subgroups with divergent clinical
features and survival outcomes.
Consensus on the analysis of basal-like breast cancer
subtypes: a literature overview
In this section, we further established a consensus on
the description of basal-like subgroups (Basal I and Basal
II) by comparing our results with other achievements
across the literature [10, 19–21, 31], as per the focus of
each study. Notably, most of them have centred on the
classification of triple-negative entities, a more hetero-
geneous group than basal-like. For instance, among the
six intrinsic TNBC subtypes defined by Lehmann et al.
(2011) [19], three were considered relevant for further
comparisons against the proposed basal-like subgroups:
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Table 5 Cytobands associated with significant CNA acquisitions
Type Cytobands Training set Validation set
p-value p-value

































Chromosome aberrations in cytobands are classified into two major types:
amplifications/gains and deletions/losses. The p-values were calculated using the
binomial test with respect to the global distribution
the basal-like (BL1 and BL2) and the immunomodula-
tory (IM). The groups were described based on cell cycle
regulation, DNA damage response and immunomodu-
latory related-genes, respectively. These genes hint to
the involvement of similar mechanisms differentiating
between Basal I and Basal II, indicating that both classifi-
cations are somehow related. Genes (G1) with high node
centrality values in Basal II, such as HJURP and TPX2
have been linked to aberrant proliferation networks, cell
invasion and metastasis in breast cancer, in line with the
definition of BL1 [19]. In addition, genes (G2) defining
the Basal I subgroup, including CXCR6, HCST, C3AR1,
GBP4, LY96,ANKRD22, FPR3 and FCGR2A, have associa-
tion with immune activation and inflammatory response,
closer to IM [19]. Major regulations involving these genes
support the existence of the two subgroups, even though
the pool of samples were considerably distinct, BLBCs and
TNBCs.
In the recent classification of TNBCs performed by
Burstein et al. (2014) [20], two groups were described:
the basal-like immune-activated (BLIA) and immune-
suppressed (BLIS) subtypes, corresponding to the best
and worst prognosis, respectively. In BLIA, tumours
display an over-expression of Stat signal transduction
molecules and cytokines; in BLIS, high levels of the
immunosuppressing molecule VTCN1. The mechanisms
defining BLIA follow the characteristics of Basal I, and
BLIS follows Basal II. For example, Basal I and BLIA
[20] contain common genes and/or genes belonging to
the same family, such as CXCL9/10/11/13, GBP4/5 and
CD2/24. Similarly, Jézéquel et al. (2015) [21] identi-
fied two relevant subtypes: basal-like with low immune
response and high M2-like macrophages (C2), and basal-
enriched with high immune response and low M2-like
macrophages (C3). The defined basal-like and basal-
enriched groups shared evident similarities with Basal
II and Basal I, respectively, and corroborated with our
study in terms of probe signature and functionality. With
regards to the TNBC classification, however, Lehmann
et al. (2011) [19], Burstein et al. (2014) [20] and Jézéquel
et al. (2015) [21] partially support each other.
An alternative approach to differentiating two sub-
groups of basal-like – associated with either a low or high
risk of disease relapse – has been tested by Hallett et al.
(2012) [10], using a 14-gene signature. Among the genes
in the signature, RPL3 andGPR27 were listed as keymark-
ers of relapse, while RPL36AL and GPR65 appeared as
variants in the 80 survival-related probes. In the same
direction, Sabatier et al. (2011) [31] identified a 28-kinase
metagene signature – associated with disease-free sur-
vival and immune response – used to divide the BLBCs
into two groups: ‘Immune High’ and ‘Immune Low’.
This approach revealed key genes, including IL2RG/B,
GBP2, CCR5/7, CXCR3/5/6 and CXCL9/13, related to
their family members in our signature, such as IL2RA,
GBP4, CCR1, CXCR6 and CXCL11. These genes appeared
over-expressed in ‘Immune High’ [31] and in Basal I
subgroup, when compared to ‘Immune Low’ [31] and
Basal II.
Integrating these observations, there is a clear con-
sensus on the segregation of basal-like breast cancers
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into at least two subgroups. Basal I (Immune Active)
show molecular overlaps and phenotypic similarities with
BLIA [20], IM [19] and C3 [21]; Basal II (High Prolif-
erative) matched with BLIS [20] and C2 [21]. The com-
prehensive genomic and transcriptomic characterisation
of the two subgroups, provided in this study, will lead
to the better understanding of the mechanisms involved
in basal-like tumours and to the identification of groups
of patients with distinct disease outcome, supported by
additional survival features [10, 31]. The latter is crucial
for improving the clinical decision-making and for help-
ing tailor treatments that are focused on the immune
system manipulation and the cell cycle pathway interven-
tion. In general, tumours with activated immune response
have shown a favourable prognosis [15] and are likely to
respond to chemotherapy [31], whereas the high prolif-
erative ones have revealed increased risk of metastasis
and recurrence [18]. In this context, patients at a low risk
should follow more conservative therapies and those at
high risk should receive more effective drugs for improv-
ing individual response, towards a more personalised
medicine.
Conclusion
Studies have demonstrated that the heterogeneity of
BLBCs extends beyond the classic immunohistochem-
istry. Although several clinicopathological features have
been used to discriminate between low- and high-risk
patients, the identification of novel biomarkers with
prognostic value remains an urgent need for improv-
ing breast cancer management. The 80-probe signature
defined in this study, associated with varying survival out-
comes, contains putative markers of disease progression
and represents a promising asset for clinical applica-
tions. The integrated assessment of miRNA expression
and CNA information, ultimately, contributes towards the
definition of more comprehensive profiles of basal-like
tumours. The importance of defining groups-at-risk of
BLBCs is reflected in the impact of survival-related fea-
tures in clinical settings and, more importantly, in therapy
response.
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